- <![CDATA[FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML]]><![CDATA[The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.]]>onclive · 2mo ago↗ source
- <![CDATA[FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma]]><![CDATA[The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.]]>onclive · 2mo ago↗ source
- <![CDATA[Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML]]><![CDATA[Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia. ]]>